Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF CHINA INJECTABLE DRUG DELIVERY DEVICES MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE CHINA INJECTABLE DRUG DELIVERY DEVICES MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 SALES VOLUME DATA
2.2.12 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.13 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 CHINA INJECTABLE DRUG DELIVERY DEVICES MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 CHALLENGES
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
5.1 PESTEL ANALYSIS
5.2 PORTER'S FIVE FORCES MODEL
6 INDUSTRY INSIGHTS
6.1 MICRO AND MACRO ECONOMIC FACTORS
6.2 PENETRATION AND GROWTH PROSPECT MAPPING
6.3 KEY PRICING STRATEGIES
6.4 INTERVIEWS WITH SPECIALIST
6.5 ANALYIS AND RECOMMENDATION
7 INTELLECTUAL PROPERTY (IP) PORTFOLIO
7.1 PATENT QUALITY AND STRENGTH
7.2 PATENT FAMILIES
7.3 LICENSING AND COLLABORATIONS
7.4 COMPETITIVE LANDSCAPE
7.5 IP STRATEGY AND MANAGEMENT
7.6 OTHER
8 COST ANALYSIS BREAKDOWN
9 TECHNOLOGY ROADMAP
10 INNOVATION TRACKER AND STRATEGIC ANALYSIS
10.1 MAJOR DEALS AND STRATEGIC ALLIANCES ANALYSIS
10.1.1 JOINT VENTURES
10.1.2 MERGERS AND ACQUISITIONS
10.1.3 LICENSING AND PARTNERSHIP
10.1.4 TECHNOLOGY COLLABORATIONS
10.1.5 STRATEGIC DIVESTMENTS
10.2 NUMBER OF PRODUCTS IN DEVELOPMENT
10.3 STAGE OF DEVELOPMENT
10.4 TIMELINES AND MILESTONES
10.5 INNOVATION STRATEGIES AND METHODOLOGIES
10.6 RISK ASSESSMENT AND MITIGATION
10.7 FUTURE OUTLOOK
11 REGULATORY COMPLIANCE
11.1 REGULATORY AUTHORITIES
11.2 REGULATORY CLASSIFICATIONS
11.2.1 CLASS I
11.2.2 CLASS II
11.2.3 CLASS III
11.3 REGULATORY SUBMISSIONS
11.4 INTERNATIONAL HARMONIZATION
11.5 COMPLIANCE AND QUALITY MANAGEMENT SYSTEMS
11.6 REGULATORY CHALLENGES AND STRATEGIES
12 REIMBURSEMENT FRAMEWORK
13 OPPUTUNITY MAP ANALYSIS
14 INSTALLED BASE DATA
15 VALUE CHAIN ANALYSIS
16 HEALTHCARE ECONOMY
16.1 HEALTHCARE EXPENDITURE
16.2 CAPITAL EXPENDITURE
16.3 CAPEX TRENDS
16.4 CAPEX ALLOCATION
16.5 FUNDING SOURCES
16.6 INDUSTRY BENCHMARKS
16.7 GDP RATION IN OVERALL GDP
16.8 HEALTHCARE SYSTEM STRUCTURE
16.9 GOVERNMENT POLICIES
16.1 ECONOMIC DEVELOPMENT
17 CHINA INJECTABLE DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE
17.1 OVERVIEW
17.2 CONVENTIONAL DRUG DELIVERY DEVICES
17.2.1 BY TYPE
17.2.1.1. STAKED NEEDLE
17.2.1.2. LUER LOCK
17.2.2 BY SAFETY
17.2.2.1. STANDARD SYRINGES
17.2.2.2. SAFETY SYRINGES
17.2.3 BY MATERIAL
17.2.3.1. GALSS
17.2.3.2. PLASTIC
17.2.4 BY DRUG LOADING
17.2.4.1. FILLABLE
17.2.4.2. PRE-FILLED
17.2.5 BY USABILITY
17.2.5.1. DISPOSABLE SYRINGES
17.2.5.2. REUSABLE SYRINGES
17.3 SELF-INJECTABLE DRUG DELIVERY DEVICES
17.3.1 NEEDLE-FREE INJECTORS
17.3.1.1. BY TYPE
17.3.1.1.1. JET BASED NEEDLE-FREE INJECTORS
17.3.1.1.1.1 BY TYPE
17.3.1.1.1.1.1. HIGH-PRESSURE JET INJECTORS
17.3.1.1.1.1.2. LOW-PRESSURE JET INJECTORS
17.3.1.1.1.2 BY USABILITY
17.3.1.1.1.2.1. REUSABLE
17.3.1.1.1.2.2. SINGLE-USE
17.3.1.1.2. SPRING BASED NEEDLE-FREE INJECTORS
17.3.1.1.2.1 SINGLE-USE SPRING BASED NEEDLE-FREE INJECTORS
17.3.1.1.2.2 REUSABLE SPRING BASED NEEDLE-FREE INJECTORS
17.3.1.1.2.2.1. PRE-FILLED
17.3.1.1.2.2.2. FILLABLE
17.3.1.1.3. LASER POWERED NEEDLE-FREE INJECTORS
17.3.1.2. BY SITE OF DELIVERY
17.3.1.2.1. INTRA DERMAL INJECTORS
17.3.1.2.2. INTRAMUSCULAR INJECTORS
17.3.1.2.3. SUBCUTANEOUS INJECTORS
17.3.1.3. BY DRUG LOADING
17.3.1.3.1. FILLABLE NEEDLE-FREE INJECTORS
17.3.1.3.2. PRE-FILLED NEEDLE-FREE INJECTORS
17.3.1.3.3. BY USABILITY
17.3.1.3.4. DISPOSABLE NEEDLE-FREE INJECTORS
17.3.1.3.5. REUSABLE NEEDLE-FREE INJECTORS
17.3.2 PEN INJECTORS
17.3.2.1. BY PRODUCT TYPE
17.3.2.1.1. SINGLE CHAMBERED PEN INJECTORS
17.3.2.1.2. DUAL CHAMBERED PEN INJECTORS
17.3.2.2. BY DESIGN
17.3.2.2.1. STANDARDIZED PEN INJECTORS
17.3.2.2.2. CUSTOMIZED PEN INJECTORS
17.3.2.3. BY USABILITY
17.3.2.3.1. DISPOSABLE PEN INJECTORS
17.3.2.3.2. REUSABLE PEN INJECTORS
17.3.2.4. BY TECHNOLOGY
17.3.2.4.1. SMART INJECTION PEN
17.3.2.4.2. AUTOMATIC INJECTION PEN
17.3.2.4.3. MANUAL INJECITON PEN
17.3.3 WEARABLE INJECTORS
17.3.3.1. BY PRODUCT TYPE
17.3.3.1.1. ON-BODY INJECTORS
17.3.3.1.1.1 ADHESIVE
17.3.3.1.1.2 BELT-WORN
17.3.3.1.1.2.1. MOTOR-DRIVEN
17.3.3.1.1.2.2. SPRING-POWERED
17.3.3.1.2. PATCH-BASED INJECTORS
17.3.3.1.2.1 BY TYPE
17.3.3.1.2.1.1. MECHANICAL
17.3.3.1.2.1.2. ELECTRONIC
17.3.3.1.2.2 BY ADHESION
17.3.3.1.2.2.1. ADHESIVE
17.3.3.1.2.2.2. NON-ADHESIVE
17.3.3.1.3. IMPLANTABLE INJECTORS
17.3.3.1.3.1 SUNCUTANEOUS
17.3.3.1.3.2 INTRAMUSCULAR
17.3.3.2. BY TECHNOLOGY
17.3.3.2.1. SMART INJECTORS
17.3.3.2.2. MANUAL INJECTORS
18 CHINA INJECTABLE DRUG DELIVERY DEVICES MARKET, BY APPLICATION
18.1 OVERVIEW
18.2 HORMONAL DISORDERS
18.2.1 DIABETES
18.2.2 ANTITHROMBOTIC/THROMBOLYTIC THERAPY
18.2.3 REPRODUCTIVE HEALTH DISEASE
18.2.4 ANEMIA
18.2.5 OSTEOPOROSIS
18.2.6 GROWTH HORMONE DEFICIENCY
18.2.7 OTHERS
18.3 ONCOLOGY
18.4 AUTOIMMUNE DISORDERS
18.4.1 RHEUMATOID ARTHRITIS
18.4.2 MULTIPLE SCLEROSIS
18.4.3 CHRON’S DISEASE
18.4.4 PSORIASIS
18.4.5 OTHERS
18.5 RARE DISEASES
18.6 PAIN MANAGEMENT
18.7 OTHERS
19 CHINA INJECTABLE DRUG DELIVERY DEVICES MARKET, BY USABILITY
19.1 OVERVIEW
19.2 SINGLE-USE
19.3 REUSABLE
20 CHINA INJECTABLE DRUG DELIVERY DEVICES MARKET, BY PURPOSE
20.1 OVERVIEW
20.2 PREVENTIVE CARE AND IMMUNIZATION
20.3 THERAPEUTIC CARE
21 CHINA INJECTABLE DRUG DELIVERY DEVICES MARKET, BY AGE GROUP
21.1 OVERVIEW
21.2 PEDIATRIC
21.3 ADULT
21.4 GERIARTIC
22 CHINA INJECTABLE DRUG DELIVERY DEVICES MARKET, BY END USER
22.1 OVERVIEW
22.2 HOSPITALS
22.3 CLINICS
22.4 HOMECARE
22.5 ACADEMIC AND RESEARCH INSTITUTES
22.6 OTHERS
23 CHINA INJECTABLE DRUG DELIVERY DEVICES MARKET, BY DISTRIBUTION CHANNEL
23.1 OVERVIEW
23.2 DIRECT TENDER
23.3 RETAIL SALES
23.4 OTHERS
24 CHINA INJECTABLE DRUG DELIVERY DEVICES MARKET, COMPANY LANDSCAPE
24.1 COMPANY SHARE ANALYSIS
24.2 MERGERS & ACQUISITIONS
24.3 NEW PRODUCT DEVELOPMENT & APPROVALS
24.4 EXPANSIONS
24.5 REGULATORY CHANGES
24.6 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
25 CHINA INJECTABLE DRUG DELIVERY DEVICES MARKET, SWOT AND DBMR ANALYSIS
26 CHINA INJECTABLE DRUG DELIVERY DEVICES MARKET, COMPANY PROFILE
26.1 BD
26.1.1 COMPANY OVERVIEW
26.1.2 REVENUE ANALYSIS
26.1.3 GEOGRAPHIC PRESENCE
26.1.4 PRODUCT PORTFOLIO
26.1.5 RECENT DEVELOPMENTS
26.2 YPSOMED
26.2.1 COMPANY OVERVIEW
26.2.2 REVENUE ANALYSIS
26.2.3 GEOGRAPHIC PRESENCE
26.2.4 PRODUCT PORTFOLIO
26.2.5 RECENT DEVELOPMENTS
26.3 GERRESHEIMER AG
26.3.1 COMPANY OVERVIEW
26.3.2 REVENUE ANALYSIS
26.3.3 GEOGRAPHIC PRESENCE
26.3.4 PRODUCT PORTFOLIO
26.3.5 RECENT DEVELOPMENTS
26.4 WEST PHARMACEUTICAL SERVICES, INC.
26.4.1 COMPANY OVERVIEW
26.4.2 REVENUE ANALYSIS
26.4.3 GEOGRAPHIC PRESENCE
26.4.4 PRODUCT PORTFOLIO
26.4.5 RECENT DEVELOPMENTS
26.5 KDL CORP.
26.5.1 COMPANY OVERVIEW
26.5.2 REVENUE ANALYSIS
26.5.3 GEOGRAPHIC PRESENCE
26.5.4 PRODUCT PORTFOLIO
26.5.5 RECENT DEVELOPMENTS
26.6 CHANGZHOU HOLINX INDUSTRIES CO., LTD
26.6.1 COMPANY OVERVIEW
26.6.2 REVENUE ANALYSIS
26.6.3 GEOGRAPHIC PRESENCE
26.6.4 PRODUCT PORTFOLIO
26.6.5 RECENT DEVELOPMENTS
26.7 TERUMO CORPORATION,
26.7.1 COMPANY OVERVIEW
26.7.2 REVENUE ANALYSIS
26.7.3 GEOGRAPHIC PRESENCE
26.7.4 PRODUCT PORTFOLIO
26.7.5 RECENT DEVELOPMENTS
26.8 SCHOTT PHARMA
26.8.1 COMPANY OVERVIEW
26.8.2 REVENUE ANALYSIS
26.8.3 GEOGRAPHIC PRESENCE
26.8.4 PRODUCT PORTFOLIO
26.8.5 RECENT DEVELOPMENTS
26.9 WEIGAO GROUP
26.9.1 COMPANY OVERVIEW
26.9.2 REVENUE ANALYSIS
26.9.3 GEOGRAPHIC PRESENCE
26.9.4 PRODUCT PORTFOLIO
26.9.5 RECENT DEVELOPMENTS
26.1 NOVO NORDISK A/S
26.10.1 COMPANY OVERVIEW
26.10.2 REVENUE ANALYSIS
26.10.3 GEOGRAPHIC PRESENCE
26.10.4 PRODUCT PORTFOLIO
26.10.5 RECENT DEVELOPMENTS
26.11 WANHAI MEDICAL INSTRUMENTS CO., LTD.
26.11.1 COMPANY OVERVIEW
26.11.2 REVENUE ANALYSIS
26.11.3 GEOGRAPHIC PRESENCE
26.11.4 PRODUCT PORTFOLIO
26.11.5 RECENT DEVELOPMENTS
26.12 NIPRO PHARMA CORPORATION
26.12.1 COMPANY OVERVIEW
26.12.2 REVENUE ANALYSIS
26.12.3 GEOGRAPHIC PRESENCE
26.12.4 PRODUCT PORTFOLIO
26.12.5 RECENT DEVELOPMENTS
26.13 PFIZER INC.
26.13.1 COMPANY OVERVIEW
26.13.2 REVENUE ANALYSIS
26.13.3 GEOGRAPHIC PRESENCE
26.13.4 PRODUCT PORTFOLIO
26.13.5 RECENT DEVELOPMENTS
26.14 BAXTER.
26.14.1 COMPANY OVERVIEW
26.14.2 REVENUE ANALYSIS
26.14.3 GEOGRAPHIC PRESENCE
26.14.4 PRODUCT PORTFOLIO
26.14.5 RECENT DEVELOPMENTS
26.15 TELEFLEX INCORPORATED
26.15.1 COMPANY OVERVIEW
26.15.2 REVENUE ANALYSIS
26.15.3 GEOGRAPHIC PRESENCE
26.15.4 PRODUCT PORTFOLIO
26.15.5 RECENT DEVELOPMENTS
26.16 MEDTRONIC
26.16.1 COMPANY OVERVIEW
26.16.2 REVENUE ANALYSIS
26.16.3 GEOGRAPHIC PRESENCE
26.16.4 PRODUCT PORTFOLIO
26.16.5 RECENT DEVELOPMENTS
26.17 OWEN MUMFORD
26.17.1 COMPANY OVERVIEW
26.17.2 REVENUE ANALYSIS
26.17.3 GEOGRAPHIC PRESENCE
26.17.4 PRODUCT PORTFOLIO
26.17.5 RECENT DEVELOPMENTS
26.18 STEVANATO GROUP.
26.18.1 COMPANY OVERVIEW
26.18.2 REVENUE ANALYSIS
26.18.3 GEOGRAPHIC PRESENCE
26.18.4 PRODUCT PORTFOLIO
26.18.5 RECENT DEVELOPMENTS
26.19 PHILLIPS-MEDISIZE
26.19.1 COMPANY OVERVIEW
26.19.2 REVENUE ANALYSIS
26.19.3 GEOGRAPHIC PRESENCE
26.19.4 PRODUCT PORTFOLIO
26.19.5 RECENT DEVELOPMENTS
26.2 WUXI NEST BIOTECHNOLOGY CO.,LTD
26.20.1 COMPANY OVERVIEW
26.20.2 REVENUE ANALYSIS
26.20.3 GEOGRAPHIC PRESENCE
26.20.4 PRODUCT PORTFOLIO
26.20.5 RECENT DEVELOPMENTS
26.21 BOEHRINGER INGELHEIM
26.21.1 COMPANY OVERVIEW
26.21.2 REVENUE ANALYSIS
26.21.3 GEOGRAPHIC PRESENCE
26.21.4 PRODUCT PORTFOLIO
26.21.5 RECENT DEVELOPMENTS
26.22 ALK
26.22.1 COMPANY OVERVIEW
26.22.2 REVENUE ANALYSIS
26.22.3 GEOGRAPHIC PRESENCE
26.22.4 PRODUCT PORTFOLIO
26.22.5 RECENT DEVELOPMENTS
26.23 CHINA GRAND PHARMACEUTICAL AND HEALTHCARE HOLDINGS LIMITED
26.23.1 COMPANY OVERVIEW
26.23.2 REVENUE ANALYSIS
26.23.3 GEOGRAPHIC PRESENCE
26.23.4 PRODUCT PORTFOLIO
26.23.5 RECENT DEVELOPMENTS
26.24 LILLY
26.24.1 COMPANY OVERVIEW
26.24.2 REVENUE ANALYSIS
26.24.3 GEOGRAPHIC PRESENCE
26.24.4 PRODUCT PORTFOLIO
26.24.5 RECENT DEVELOPMENTS
26.25 VIATRIS INC.
26.25.1 COMPANY OVERVIEW
26.25.2 REVENUE ANALYSIS
26.25.3 GEOGRAPHIC PRESENCE
26.25.4 PRODUCT PORTFOLIO
26.25.5 RECENT DEVELOPMENTS
26.26 SANOFI
26.26.1 COMPANY OVERVIEW
26.26.2 REVENUE ANALYSIS
26.26.3 GEOGRAPHIC PRESENCE
26.26.4 PRODUCT PORTFOLIO
26.26.5 RECENT DEVELOPMENTS
26.27 SHADONG WEGO
26.27.1 COMPANY OVERVIEW
26.27.2 REVENUE ANALYSIS
26.27.3 GEOGRAPHIC PRESENCE
26.27.4 PRODUCT PORTFOLIO
26.27.5 RECENT DEVELOPMENTS
27 RELATED REPORTS
28 CONCLUSION
29 QUESTIONNAIRE
30 ABOUT DATA BRIDGE MARKET RESEARCH
